Login to Your Account



XOMA Enters Phase III Testing With Inflammation Candidate

By Catherine Shaffer
Staff Writer

Thursday, June 28, 2012
Enrollment is now open in two clinical trials of XOMA Corp.'s gevokizumab for inflammatory diseases. One trial, a Phase III study, will evaluate gevokizumab for noninfectious uveitis, while a Phase II trial will look at gevokizumab for erosive osteoarthritis of the hand.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription